Seeking Alpha

Shares of BioCryst Pharmaceuticals (BCRX) shoot up 11% premarket after the firm announces...

Shares of BioCryst Pharmaceuticals (BCRX) shoot up 11% premarket after the firm announces positive top-line results for a Phase 2 study of its gout treatment that met its main goal.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)